Navigation Links
Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
Date:6/16/2008

SAN DIEGO, June 16 /PRNewswire/ -- Victory Pharma, Inc., a specialty pharmaceutical company focused on pain and related areas of medicine, today announced the recent initiation of the first of two clinical studies for MGX006 antiemetic pivotal clinical program.

"Data from the Phase 2 studies confirming pivotal formulation selection and end-of-phase 2 discussions with the FDA regarding the registration study designs provides confidence that MGX006 will move rapidly through pivotal development," explained Dr. Shawn Scranton, Vice President of Scientific Operations. "Victory is pleased with the results to date and is confident that MGX006 will provide an important therapeutic alternative for patients suffering from emesis of various etiologies," continued Dr. Scranton.

"MGX006 represents a key milestone for Victory," stated Matthew Heck, President and CEO. "This novel approach to antiemetic therapy is the company's first internally developed pipeline product, demonstrating our commitment to developing solutions for unmet medical needs. We look forward to marketing MGX006 in the U.S. with our specialty sales force."

About MGX006

MGX006 utilizes a proprietary formulation applied to a previously approved antiemetic agent. The formulation was created utilizing patented technology through a partnership and has properties that make MGX006 ideally suited for the treatment of nausea and vomiting.

About Victory Pharma, Inc.

Victory Pharma, Inc. is a private San Diego based specialty pharmaceutical company focused on acquiring, marketing and developing proprietary pain and related products. Victory markets its existing pain products through its field sales force headquartered in Cary, NC, and is currently developing several products in pain and pain complementary markets. Further information regarding Victory is available at http://www.VictoryPharma.com.


'/>"/>
SOURCE Victory Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... HELSINKI, December 3 After two...ccess in their field, Lightlake Therapeutics, expe...lecting and gene testing,subjects for a trial of a...,World Health Organisation has described as a glob..., A Phase II trial for the everyday treatment ...
(Date:12/2/2009)...YORK, Dec. 2 Reportlinker.com anno...le in its catalogue: ,, Cardiac Pacemakers - ...linker.com/p0164335/Cardiac-Pacemakers---A-World-M...itute a major segment in a rapidly expanding cardi...cemakers market is characterized by relatively mat...
(Date:12/2/2009)...O, Calif., Dec. 2 Varian... 25, 2009, Varian, Inc. filed with the U.S. Securi...Form 10-K for the fiscal year ended October 2, 200... Company,s web site at www.varianinc.com, by click..."10-K" in the table shown. Stockholders may recei...
Breaking Medicine Technology:Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 2Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 3Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 4Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 1Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 2Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 3Independence Blue Cross Harnesses Technology to Connect the Dots on Patient Care 52780 4Olympus Managed Health Care Receives Third Party Administrative License in State of Florida 52776 1Digitas Health Expands Adding Two Key Locations 13208 1Digitas Health Expands Adding Two Key Locations 13208 2Digitas Health Expands Adding Two Key Locations 13208 3Digitas Health Expands Adding Two Key Locations 13208 4
... Surface Treatment Maximizes,Endothelialization; R...Term,Dual Antiplatelet Therapy, WASHINGTON, Oct. ...Devices and Futuristic Therapies" session during t...eutics (TCT) scientific,symposium, sponsored by th...-month follow-up data from the ATLANTA Trial. The ...
...Cancer Populations Facilitates ...3 Rubicon Genomics, Inc. today,announced an agree...r The,Cancer Atlas Genome Project., Rubicon Genom...genomic,DNA from 3,000 tissue and blood samples fr...le Genome Amplification technology was judged best...
Other Medicine Technology:12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3
(Date:12/3/2009)...e-USNewswire/ -- A recent study conducted by the C... HealthCare, found that text messaging is an innov...aily use of sunscreen, and this technology may hav...ealth initiatives. Study participants who received...nearly twice as adherent to applying sunscreen com...
(Date:12/3/2009)... created by a single case of H1N1 influenza indica..., social distancing and the use of antiviral drugs... suggests an epidemiological modelling study http...ed in CMAJ ( Canadian Medical Association Journ...from laboratory-confirmed cases of H1N1 between Ap...
(Date:12/3/2009)...e heart is stopped and restarted, the patient,s li...ly damaged. Therapeutic hypothermia, a treatment i...and maintained several degrees below normal for a ...armful effects and improve survival in adults. , ...f its kind, physician-scientists are evaluating th...
(Date:12/3/2009)...ay is still too many - stalled momentum puts milli... Atlanta, GA, Geneva, New York, NY and Washingt...tiative announced today that measles deaths worldw...imated 733 000 in 2000 to 164 000 in 2008. However... in measles deaths if vaccination efforts are not ...
(Date:12/3/2009)...sed to smoke are at risk of lung cancer , ...ectal cancer to the list of malignancies caused by...between the two. , And other studies are provid...o quit: Two papers published in the December issue... themed issue on tobacco, strengthen the case for ...
Breaking Medicine News(10 mins):Health News:Cell Phone Text Messaging Technology is a Low-Cost, Effective Way to Improve Use of Sunscreen and Reduce Risk of Skin Cancer, According to a New Study 2Health News:Cell Phone Text Messaging Technology is a Low-Cost, Effective Way to Improve Use of Sunscreen and Reduce Risk of Skin Cancer, According to a New Study 3Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Cooling may benefit children after cardiac arrest 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 2Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 3Health News:Global Measles Deaths Drop By 78%, But Resurgence Likely 4Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4
... 2 EIN News has announced the launch of a new hea...r. , , With new advances in medicine, more an...s one of the key components to surviving cancer. ...EIN News is introducing Brain Cancer News Today to...
...y researchers at The University of Nottingham has ... cancer. , The research, published in the journal..., USA and funded by a 72,000 grant from the Britis...y for possible new treatments and early screening ...
... 2 /EIN News/ -- EIN News has announced the launc...on prostate cancer. , , With new advances in ...hat information is one of the key components to su... drugs to treat it, EIN News is introducing Prosta...
...issing Opportunities to Connect - , , - Only ...ption Drug Abuse Dangers - , , NEW YORK, Dec....ship for a Drug-Free America and MetLife Foundatio...th their kids about drug and alcohol use. The nati...
...aboration with Moonview Sanctuary, a Dedicated Wel...to Launch in February 2009 , , SANTA MONICA,...www.hotelcasadelmar.com/ ) offers guests the uniqu... menu of programs focusing on mental and physical ...
...hoveling ruin your winter wonderland , , ROSE... unpleasant task -- this mundane seasonal chore co...n possible injuries to the back, shoulder muscles ...you stay safe while clearing snow so you can still...
Other Medicine News:Health News:EIN News Introduces 'Brain Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Gene which protects against lung cancer identified 2Health News:EIN News Introduces 'Prostate Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 2Health News:Bridging the Technology Gap: Study Confirms Teens Open to Discussing Drugs and Alcohol With Parents By Email, Cell Phones 3Health News:Photos: Hotel Casa del Mar Offers New 'Wellness Your Way' Program 2Health News:Let it Snow, Let it Snow, Let it Snow 2Health News:Let it Snow, Let it Snow, Let it Snow 3Health News:Let it Snow, Let it Snow, Let it Snow 4
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: